Spiro-2'-one | 16133-64-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: Spiro-2'-one
• 英文别名: 2-Spirocyclopropylbicyclo<2.2.1>heptanon；Spiro；spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropane]-3-one；spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-one；spiro[bicyclo[2.2.1]heptane-3,1'-cyclopropane]-2-one
• CAS: 16133-64-5
• 化学式: C₉H₁₂O
• 分子量: 136.194
• InChiKey: ZYFYCMULISNLFT-UHFFFAOYSA-N

物化性质

• 沸点：
  223.2±8.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Spiro-2'-one 在 lithium aluminium tetrahydride 作用下， 生成 endo-Spiro
  参考文献：
  名称：

  Preparation of some spiro-cyclopropyl norbornyl compounds

  摘要：

  DOI：

  10.1021/jo01269a114
• 作为产物：
  描述：

  二碘甲烷 、 3-亚甲基-2-降冰片酮 在 zinc/copper couple 作用下， 以 乙醚 为溶剂， 反应 22.0h， 生成 Spiro-2'-one
  参考文献：
  名称：

  [EN] NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS
  [FR] RÉCEPTEURS NICOTINIQUES UTILES COMME ANTAGONISTES NON COMPÉTITIFS

  摘要：

  本发明涉及调节尼古丁受体作为非竞争性拮抗剂的化合物，其合成方法，使用方法以及药物组成物。

  公开号：

  WO2011149859A1

文献信息

• N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
  申请人：Hashimoto Masaya

  公开号：US20070015792A1

  公开（公告）日：2007-01-18

  The invention provides the compounds represented by the formula (I) in which, R stands for a dihydroxy-substituted C 1 -C 6 alkyl group, and Cy stands for an optionally substituted C 6 -C 10 bi- or tri-cyclic aliphatic carbocyclic group. These compounds act as nociceptin receptor antagonist, and are useful, for example, as relievers against tolerance to narcotic analgesic, dependence on narcotic analgesic or addiction; analgesic enhancers; antiobestic or appetite suppressors; treating or prophylactic agents for cognitive impairment and dementia/amnesia; agents for treating developmental cognitive abnormality; remedy for schizophrenia; agents for treating neurodegenerative diseases; anti-depressant or treating agents for affective disorder; treating or prophylactic agents for diabetes insipidus; treating or prophylactic agents for polyuria; and remedy for hypotension and the like.

  该发明提供了由式(I)表示的化合物，其中R代表二羟基取代的C1-C6烷基基团，Cy代表一个可选择取代的C6-C10双环或三环脂肪环碳环基团。这些化合物作为痛觉受体拮抗剂，例如，可用作缓解对麻醉镇痛药的耐受性、对麻醉镇痛药的依赖或成瘾的药物；镇痛增强剂；抗肥胖或食欲抑制剂；治疗或预防认知障碍和失忆症/健忘症的药物；治疗发育性认知异常的药物；治疗精神分裂症的药物；治疗神经退行性疾病的药物；抗抑郁或治疗情感障碍的药物；治疗或预防尿崩症的药物；治疗或预防多尿症的药物；以及治疗低血压等的药物。
• NICOTINIC RECEPTOR NON-COMPETITIVE ANTAGONISTS
  申请人：Akireddy Srinivasa Rao

  公开号：US20130203860A1

  公开（公告）日：2013-08-08

  The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.

  本发明涉及一种调节尼古丁受体作为非竞争性拮抗剂的化合物，其合成方法，使用方法以及它们的药物组成物。
• N-DIHYDROXYALKYL-SUBSTITUTED 2-OXOIMIDAZOLE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1914232A1

  公开（公告）日：2008-04-23

  The invention provides the compounds represented by the formula (I) in which, R stands for a dihydroxy-substituted C1- C6 alkyl group, and Cy stands for an optionally substituted C6 - C10 bi- or tri-cyclic aliphatic carbocyclic group. These compounds act as nociceptin receptor antagonist, and are useful, for example, as relievers against tolerance to narcotic analgesic, dependence on narcotic analgesic or addiction; analgesic enhancers; antiobestic or appetite suppressors; treating or prophylactic agents for cognitive impairment and dementia/amnesia; agents for treating developmental cognitive abnormality; remedy for schizophrenia; agents for treating neurodegenerative diseases; anti-depressant or treating agents for affective disorder; treating or prophylactic agents for diabetes insipidus; treating or prophylactic agents for polyuria; and remedy for hypotension and the like.

  本发明提供了式 (I) 所代表的化合物 其中，R 代表二羟基取代的 C1- C6 烷基，Cy 代表任选取代的 C6 - C10 双环或三环脂族碳环基团。这些化合物具有痛觉素受体拮抗剂的作用，例如，可用于缓解对麻醉性镇痛剂的耐受性、对麻醉性镇痛剂的依赖性或成瘾性；镇痛增强剂；抗镇静剂或食欲抑制剂；认知障碍和痴呆/失智症的治疗或预防剂；治疗认知发育异常的药物；治疗精神分裂症的药物；治疗神经退行性疾病的药物；抗抑郁剂或治疗情感障碍的药物；治疗或预防糖尿病的药物；治疗或预防多尿症的药物；以及治疗低血压的药物等。
• Nicotinic receptor non-competitive antagonists
  申请人：Catalyst Biosciences, Inc.

  公开号：US10258582B2

  公开（公告）日：2019-04-16

  The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.

  本发明涉及作为非竞争性拮抗剂调节烟碱受体的化合物、其合成方法、使用方法及其药物组合物。
• Stable carbocations. 283. Carbon-13 NMR spectroscopic investigation of tertiary spiro[cyclopropane-3'-norbornan]-2'-yl cations and their rearrangements
  作者：George A. Olah、V. Prakash Reddy、Golam Rasul、G. K. Surya Prakash

  DOI：10.1021/jo00030a016

  日期：1992.2

  2'-Methylspiro[cyclopropane-3'-norbornan]-2'-yl (9), 2'-phenylspiro[cyclopropane-3'-norbornan]-2'-yl (10), and 2-cyclopropylspiro[cyclopropane-3'-norbornan]-2'-yl (11) cations were prepared from the corresponding alcohols with Magic Acid (1:1 SbF5 + FSO3H) at low temperatures and characterized by C-13 NMR spectroscopy. Cation 11 is extremely stable up to -20-degrees-C. Cation 10 rearranges to the 2-phenyl-4-methylbicyclo[3.2.1]oct-3-en-2-yl cation (13) at about -70-degrees-C. The cation 9, and its rearranged isomer 2,4-dimethylbicyclo[3.2.1]oct-3-en-2-yl cation (12), exist in an 1:1 ratio even at -90-degrees-C. The chemical shift assignments were aided by ab initio IGLO calculations. The study shows the overwhelming delocalizing ability of the 3-spirocyclopropyl group over C1-C6 sigma-bond participation. The latter nonclassical sigma-participation, however, was shown to persist to some extent even in the tertiary 2-norbornyl cations.